Everyday technologies for Alzheimer's disease care: Research findings, directions, and challenges

2009 ◽  
Vol 5 (6) ◽  
pp. 479-488 ◽  
Author(s):  
Maria C. Carrillo ◽  
Eric Dishman ◽  
Tim Plowman
1986 ◽  
Vol 20 (3) ◽  
pp. 384-385 ◽  
Author(s):  
A. F. Jorm

A meta-analysis of the literature on drug treatments for Alzheimer's disease revealed the following limitations in the dissemination of research findings: multiple publication of findings, failure to report basic descriptive statistics and failure to respond to written requests for additional information on the research. The possible reasons for these problems and remedies for them are discussed.


2017 ◽  
Vol 2017 ◽  
pp. 1-6
Author(s):  
Mark E. McCaulley ◽  
Kira A. Grush

There is no effective etiologic treatment for Alzheimer’s disease, nor is there a prophylactic medication which delays or prevents its onset. The lack of an accurate paradigm is undoubtedly related to the lack of effective means of prophylaxis and treatment. The current paradigm of beta amyloid in Alzheimer’s brains causing cognitive dysfunction must be modified. Despite failed clinical trials, research continues into amyloid-oriented treatments. The persistence of the amyloid hypothesis/paradigm is an example of anchoring and representativeness heuristics described by Kahneman and Tversky in their classic 1974 Science paper. Economic factors also contribute to the persistence of this paradigm. Paradigms impact the scientific process by the following: (1) what is studied; (2) the types of questions that are asked; (3) the structure and nature of the questions; (4) the interpretations of research findings. We review the contribution of inflammation, malfunction of the neurovascular unit, and prion disease to Alzheimer’s disease manifestations. Any or all of these are candidates for inclusion into a more accurate, inclusive, and useful new paradigm. By incorporating emerging facts and understanding into a new paradigm, we will enhance our ability to move toward effective prophylaxis and therapy for this tragic disease.


2005 ◽  
Vol 09 (09) ◽  
pp. 368-372

Forthcoming: A Vaccine for Cervical Cancer. A Safer and More Effective "Aspirin". Scientists Uncover A New Method of Producing NK Cells. Insight into the Human Genome Through the Elephant Shark. Using Gene Therapy for Alzheimer's Disease.


Author(s):  
A.M. Downing ◽  
R. Yaari ◽  
D.E. Ball ◽  
K.J. Selzler

Due to the growing global health impact of Alzheimer’s disease (AD), there is a greater need for interventions that prevent or delay the onset of clinical symptoms of this debilitating disease. Clinical trials for disease-modifying compounds in AD have shifted towards earlier stages in the spectrum of illness, including the stage prior to cognitive symptoms. A population of specific interest for clinical research includes individuals with evidence of Alzheimer’s disease pathology who are asymptomatic (ADPa). The challenges and barriers regarding medical treatment of ADPa must be identified and addressed prior to the completion of a positive clinical trial in order to accelerate the translation of research findings to clinical practice. This report applies an existing public health impact model from Spencer and colleagues (2013) to evaluate the readiness of the clinical practice environment to treat ADPa individuals if a disease-modifying agent achieves approval. We contrast the current clinical practice environment with a potential future state through investigating the effectiveness, reach, feasibility, sustainability, and transferability of the practice of treating ADPa individuals.


2018 ◽  
Vol 26 (4) ◽  
pp. 347-357 ◽  
Author(s):  
Dhamidhu Eratne ◽  
Samantha M Loi ◽  
Sarah Farrand ◽  
Wendy Kelso ◽  
Dennis Velakoulis ◽  
...  

Objectives: To provide a clinical update for general psychiatrists on the assessment and diagnosis of Alzheimer’s disease (AD), highlighting current issues regarding epidemiology, risk factors and pathophysiology from recent relevant research findings. Conclusions: Psychiatrists can apply their skills and training in the diagnosis of AD, which is based upon a comprehensive assessment comprising history, investigations, and cognitive and functional assessment, guided by accepted diagnostic criteria.


2021 ◽  
Vol 18 ◽  
Author(s):  
Manli Wang ◽  
Hang Yu ◽  
Song Li ◽  
Yang Xiang ◽  
Weidong Le

: Biological rhythms have become the research focus in recent years. Biological rhythm disruption is a common symptom of Alzheimer's disease (AD) patients, which is usually consid- ered as the late consequence of AD. Recent studies have shown that biological rhythm disruption even occurs before the onset of clinical symptoms of AD. The causal relationship between AD and biological rhythm disruption is not clear. Delineating their relationship can help understand the dis- ease mechanisms and make the early diagnosis of AD possible. This review integrates the research on the abnormal changes of the biological rhythm-related parameters in the clinical manifestations of AD patients and the roles of the biological rhythm disorders in AD. We will discuss the links be- tween biological rhythms and AD, with the focus on the bidirectionality between biological rhythms and AD processes. Collectively, these updated research findings may provide the basis for further exploring the significance of rhythm in the diagnosis and treatment of AD.


Sign in / Sign up

Export Citation Format

Share Document